While any flu vaccine offers meaningful protection for older adults against severe outcomes, enhanced formulations (high-dose, adjuvanted, or recombinant) are preferred when available due to their superior protective efficacy in this vulnerable population. This evidence-based recommendation applies in countries where these enhanced vaccine options can be accessed for elderly patients